Description du projet
Une nouvelle méthode de détection du mélanome
L’incidence du cancer de la peau a augmenté au cours des dernières décennies. Chaque année, jusqu’à 3 millions de personnes développent un cancer de la peau. Le mélanome malin est la plus dangereuse des tumeurs cutanées. Un diagnostic précoce permet d’améliorer la qualité de vie de ces patients, mais les méthodologies actuelles ne sont pas fiables et ne sont pas utilisées aussi souvent que nécessaire. Le projet MERWIS, financé par l’UE, vise à augmenter la fréquence des examens. Pour ce faire, il piste l’évolution (le changement) de chaque grain de beauté surveillé, mais avec une fréquence élevée ou très élevée. Comme la plupart des signes cliniques du mélanome sont visibles, MERWIS utilise une cabine de cartographie corporelle, une application mobile et un logiciel d’analyse qualitative des données assistée par ordinateur pour détecter tous les changements visibles du mélanome.
Objectif
However, there are several tools and solutions for aiding the melanoma detection (variable dermatoscopes, full-body mapping tools and Applications), they were not able to achieve breakthrough in the early diagnosis phase. It comes from the wrong methodologies. There are two types of available tools: 1) diagnostic tools, whit the aim of diagnosing skin-cancer without human intervention, and 2) medical equipment, which help the work of dermatologist during the examination in a doctor’s office. The problem with first methodology (artificial based skin-cancer diagnosis) is that these do not work reliable or do not work at all. The main problem of the second methodology is the very rare examination frequency. An average health conscious European adult visits skin-cancer screening in every 3-7 years.
In contrast with these, MERWIS offers a solution that focuses on increasing the examination frequency, where the system does not need to establish a full diagnosis. MERWIS only looks for evolution (change) of every single monitored mole, but with high or very high frequency.
The validated and demonstrated MERWIS prototype is based on the fact that most clinical signs of melanoma are all visible. Through using the combination of a special body-mapping cabin, a mobile application based “self dermoscopy”, and a computer assisted qualitative data analysis software we can detect all the visible changes of melanoma ABCDE. Furthermore our system uses a custom made distributed ledger technology-based network cloud solution. Based on this framework it is possible to build the MERWIS decentralized database on a maximum security level and ensure scalability.
The aim of this Phase 1 project is to carry out an extended feasibility study consisting of market assessment, business model validation, risk and IP strategy assessment, up-date and advancement of the business plan, and international pilot location selection to support the global commercialisation of our technology.
Champ scientifique
- natural sciencescomputer and information sciencesdata science
- natural sciencescomputer and information sciencessoftware
- natural sciencescomputer and information sciencesdatabases
- medical and health sciencesclinical medicineoncologyskin cancermelanoma
- social scienceseconomics and businessbusiness and managementbusiness models
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
1183 BUDAPEST
Hongrie
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.